Pascal Soriot | Executive Director and Chief Executive Officer |
Dave Fredrickson | EVP, Oncology Business Unit |
Ruud Dobber | EVP, BioPharmaceuticals Business Unit |
Marc Dunoyer | Executive Director and Chief Financial Officer |
Mene Pangalos | EVP, BioPharmaceuticals R&D |
Susan Galbraith | EVP, Oncology R&D |
Leon Wang | EVP, China and the Emerging Markets |
Aradhana Sarin | Chief Financial Officer elect |
Luisa Hector | Berenberg |
Tim Anderson | Wolfe Research |
Richard Parkes | Exane |
Keyur Parekh | Goldman Sachs |
Sachin Jain | Bank of America |
Andrew Baum | Citi |
Mark Purcell | Morgan Stanley |
Simon Baker | Redburn |
James Gordon | JPMorgan |
Emmanuel Papadakis | Deutsche Bank |
Seamus Fernandez | Guggenheim |
Steve Scala | Cowen |
Naresh Chouhan | Intron Health |
Viktor Sandberg | Svalner |
Good afternoon, Europe and good morning to the US. Welcome, ladies and gentlemen to AstraZeneca's Half Year Results 2021 Presentation Conference Call and Webcast for Investors and Analysts.
Before I hand over to AstraZeneca, I'd like to read the Safe Harbor statement. The company intends to utilize the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.